Ocular Paraneoplastic Syndromes

This is a type of paraneoplastic syndrome that affects the eyes. It happens when cancer causes the body's immune system to attack the eye tissues. This can lead to vision problems, like blurry vision or changes in eye color.

Condition

What people with Ocular Paraneoplastic Syndromes report

Every report comes from a Lived member, sent anonymously.

Have you tried Prednisone for Ocular Paraneoplastic Syndromes?

NameHow it went

About Ocular Paraneoplastic Syndromes

What It Is

Ocular paraneoplastic syndromes are rare eye disorders caused by the body's reaction to a cancer elsewhere, not by the cancer spreading into the eye. The immune system, or a substance the tumor releases, ends up damaging the retina (the light-sensing layer at the back of the eye), the optic nerve or other eye tissue. The usual result is vision loss in both eyes that develops over weeks to months. The term covers several distinct conditions. Cancer-associated retinopathy (CAR) damages the cells that detect light and often causes flashes or flickering, sensitivity to glare, patchy gaps in the field of vision and loss of sharp central vision. Melanoma-associated retinopathy (MAR) occurs with melanoma, a skin cancer, and typically causes night blindness and shimmering lights. Bilateral diffuse uveal melanocytic proliferation (BDUMP) is different: pigment cells in the eye's middle layer multiply, causing fluid to collect under the retina and cataracts to form quickly. Less common forms include inflammation inside the eye (paraneoplastic uveitis) and of the optic nerve. These syndromes matter beyond the eyes because the vision changes often appear before anyone knows a cancer is present. Recognizing them can lead to an earlier cancer diagnosis.

Causes & Risk Factors

The underlying cause is a cancer. In most forms, the immune system makes antibodies to attack the tumor, and some of those antibodies also recognize proteins that the tumor shares with the eye. Recoverin, for example, is a protein normally found in the retina's light-sensing cells that some lung cancers also produce. The antibodies then injure healthy eye tissue. BDUMP appears to work differently: researchers think a factor circulating in the blood drives the eye's pigment cells to grow. The type of cancer varies by syndrome. CAR is most often linked to lung cancer (especially small cell lung cancer) and gynecologic cancers such as ovarian and uterine cancer, though breast and many other cancers have been reported. MAR occurs with melanoma, often when it has spread or come back. BDUMP has been linked mainly to lung, gynecologic and urinary tract cancers. Most people affected are in their 50s to 70s, reflecting the ages when these cancers are common. Cancer immunotherapy drugs called immune checkpoint inhibitors, which strengthen the immune attack on tumors, can sometimes bring on or worsen these eye syndromes. Even so, these conditions are very rare: estimates suggest they affect around 1 in 10,000 people with cancer.

How It's Diagnosed

No single test confirms an ocular paraneoplastic syndrome. Diagnosis rests on a pattern: typically, vision loss in both eyes that progresses over weeks to months, eye tests showing the kind of damage these syndromes cause, and an associated cancer. Because the eye can look nearly normal early in CAR and MAR, the cause may not be obvious at a routine eye exam. An eye specialist usually uses several tests. Visual field testing maps blind spots. Optical coherence tomography (OCT), a scan that images the retina's layers, can show thinning where light-sensing cells have been lost or fluid under the retina. An electroretinogram (ERG), which measures the retina's electrical response to flashes of light, is often markedly reduced in CAR and shows a particular pattern in MAR. In BDUMP, the back of the eye often shows a distinctive patchwork of red or pigmented spots. Blood tests for anti-retinal antibodies can support the diagnosis, but they cannot confirm it on their own. Such antibodies turn up in many people without the disease, including some healthy people, and labs often disagree with each other. A negative result also does not rule it out. Doctors must also exclude look-alikes, such as inherited retinal diseases, retinal damage from medicines or toxins, and autoimmune retinopathy without cancer. If no cancer is known, the diagnosis triggers a search for one, often starting with a CT scan of the chest and sometimes a PET-CT scan (positron emission tomography combined with CT), which looks for areas of unusual activity throughout the body. In published cases, the cancer was found only after the eye problem in most people with CAR and in more than half of those with MAR or BDUMP.

Treatment Options

Treatment has two goals: control the cancer and limit further damage to vision. Finding and treating the cancer promptly comes first. In people with CAR, an early cancer diagnosis, within about six months of eye symptoms starting, has been the factor most clearly linked to better vision. In MAR, vision often improves as the melanoma shrinks. There is no agreed standard treatment for the eye disease itself, because the conditions are too rare for large trials. Corticosteroids, given as pills, by infusion or as injections or implants in the eye, are the most common choice to calm the immune attack. Other options include intravenous immunoglobulin (IVIG, antibodies pooled from donors that can dampen the immune response), plasmapheresis (filtering antibodies out of the blood) and immune-suppressing drugs such as mycophenolate or rituximab. Results have been mixed: some people stabilize or improve, while others keep losing vision. Treatment works best before many light-sensing cells have died, since lost cells do not regrow. In BDUMP, plasmapheresis appears to improve vision for a substantial share of people, and surgery for the rapidly forming cataracts can help. Paraneoplastic uveitis and optic nerve inflammation tend to respond better to corticosteroids than CAR does. Immune-suppressing treatment has to be coordinated with the cancer team. Combined with chemotherapy, it can increase side effects such as low blood counts, and some drugs used for other eye inflammation are avoided when cancer is active. For people whose eye syndrome appeared during checkpoint inhibitor immunotherapy, continuing that drug may cause permanent vision loss, so the oncologist and eye specialist weigh cancer control against vision together.

What to Expect

The outlook depends on which syndrome a person has. CAR is the most serious for vision: in published cases, roughly half of people saw their vision worsen despite treatment, and only about a third improved. MAR, paraneoplastic uveitis and optic nerve forms more often stabilize or improve, sometimes better than the outlook for the cancer itself. Outcomes in BDUMP are mixed. Because most of this evidence comes from individual case reports, an individual's course can differ. Living with these conditions usually means managing two illnesses at once. Appointments with the eye specialist, often with repeated visual field tests, OCT scans and electroretinograms, track whether vision is holding steady, alongside cancer care. Vision loss can affect reading, driving at night, moving around in dim light and independence. Low vision services, which teach practical techniques and provide magnifiers, lighting and other aids, can help people make the most of the vision they have. The eye condition can also signal changes in the cancer. Vision symptoms sometimes appear when cancer returns, so ongoing cancer follow-up remains important.

When to Seek Help

See an eye doctor promptly if vision in both eyes declines over weeks to months without a clear reason, especially with flashes or flickering lights, new trouble seeing in dim light, unusual sensitivity to glare or patchy gaps in vision. This is particularly important for people with a current or past cancer, or with risk factors such as a history of smoking. If you are receiving immune checkpoint inhibitor immunotherapy, tell your cancer team right away about any new vision change. If you have already been diagnosed, contact your eye specialist soon if vision worsens further or new symptoms appear, such as eye pain or redness, since treatment may need to change.

Questions to Ask Your Doctor

  1. 1.Which type of ocular paraneoplastic syndrome do I have, and what does that mean for my vision over time?
  2. 2.If no cancer has been found yet, what tests will we use to look for one, and how soon?
  3. 3.What are the realistic benefits and risks of treating the eye inflammation while I am also having cancer treatment?
  4. 4.How will we measure whether my vision is stable or getting worse, and how often should I be tested?
  5. 5.What low vision services or aids could help me keep reading, moving around safely and staying independent?

Last reviewed • Oct 2026

Educational content, not medical advice.